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Abstract 
Background: Regulatory guidelines require that any new medicine designed for a pediatric 
population must be demonstrated to be acceptable to that population. There is currently no 
guidance on how to conduct or report acceptability testing.  
Aim: Our objective was to undertake a review of the methods used to assess the acceptability of 
medicines within a pediatric population and use this review to propose the most appropriate 
methodology going forwards.  
Methods: A defined search strategy was used to identify literature reports of acceptability 
assessments of medicines conducted within pediatric populations. Information about the tools used 
in these studies was extracted to allow comparison across studies.   
Results: 61 articles were included in the analysis. Palatability was the most common attribute 
measured in evaluating acceptability (54/61). Simple scale methods were most commonly used with 
visual analogue scales (VAS) and hedonic scales used separately and also in combination in 34/61 
studies. Hedonic scales alone reported for 14 studies and VAS alone in just 5 studies. Other tools 
included Likert scales; forced choice or preference; surveys or questionnaires; observations of facial 
expressions during administration, or the ease or ability to swallow the dosage; the prevalence of 
complaints or refusal to take the medicine; and the time taken for a nurse to administer the 
medicine. 
Conclusions: It remains unclear which scale is the best with regards to its validity, reliability, 
feasibility and preference to assess acceptability. Further work is required to select the most 
appropriate method to justify that a medicine is acceptable to a pediatric population.  
Key Points 
• Many different methods to assess acceptability of pediatric medicines have been described 
in the literature however, this lack of standardisation in approach and methodology makes 
comparisons between products complex.  
• Few studies have defined criteria that define acceptability of a product to a pediatric 
population. 
• Simple 5-point hedonic scales or visual analogue scales are appropriate to evaluate 
acceptability going forwards provided the anchor phrases are meaningful to participants 
• Further work is required to define the most appropriate methodology to use to ensure 
acceptable medicines are available to pediatric populations. 
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1. Introduction 
Pediatric formulation development is currently a ‘hot’ topic within the pharmaceutical industry and 
substantial efforts are being invested into developing medicines that are acceptable to children. 
Acceptability of medicines for children is a challenge, yet critical to ensure adherence to treatment. 
The palatability of pediatric medicines is one of the most important formulation factors with 
potential to influence adherence to therapeutic regimens and outcomes [1]. It has been 
demonstrated that making medications more pleasing to the child can have a positive effect on 
compliance [2]. Acceptability has previously been defined as, “an overall ability of the patient and 
caregiver (defined as ‘user’) to use a medicinal product as intended (or authorised),” which often 
encompasses taste and palatability testing [3]. The European Medicines Agency (EMA) have issued 
guidance that requires acceptability to be assessed (preferably in children) yet there is no guidance 
on the methodology that should be used for this evaluation [4].  Palatability is defined as acceptable 
to the mouth so incorporates textural and olfactory attributes as well as taste. EMA guidance on the 
palatability of veterinary products proposed that voluntary acceptance rates should be >80% in 
dogs, and >70%, for all other species [5]. The lack of a standardised method to assess acceptability of 
pediatric medicines has been highlighted previously [3, 6].  
A key barrier in the development of acceptable, age-appropriate medicines is the lack of knowledge 
about what is currently considered to be acceptable to pediatric patients and how the acceptability 
of a new product should be assessed. In support of development of guidance on appropriate 
methodology to use to assess acceptability going forwards this paper reports on a systematic search 
of peer-reviewed literature on acceptability and preference testing of medicines in children to 
provide a review. 
2. Methods 
Information on methodology to assess acceptability of medicines in pediatric populations was 
sought from a literature search. Overall, the methods for the search protocol were informed by the 
Cochrane Handbook for Systematic Reviews of Interventions [7]. This review was limited to 
acceptability testing of oral dosage forms in pediatric populations. 
The literature search identified indexed publications by searching Scopus, PubMed, Embase and 
Medline databases up until May 2016. Search key words included: acceptability OR preference AND 
medicine AND (child OR infant OR pediatric OR pediatric) AND palatability OR taste OR smell OR size 
OR shape OR appearance OR swallowability. The search profile can be seen in online resource 1.  
The process to identify the most relevant research included: screening of titles and abstracts; 
selection of studies based on inclusion criteria with checks from a second reviewer; searching of 
reference lists of included studies, and contacting experts for the details of any unpublished or 
ongoing studies (EuPFI network (www.eupfi.org) and consortium members within SPaeDD-UK (Smart 
Paediatric Drug Development – UK, accelerating paediatric formulation 
development http://www.paediatricscienceuk.com)) and finally data extraction using a bespoke 
data extraction table. 
Only papers where information that specifically related to methodology to assess acceptability of 
medicines in pediatric populations was extracted and included in the results; many papers described 
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the acceptability of dosage forms but did not contain sufficient details on the methodology and 
could not be included. 
The SPaeDD-UK project is guided by a steering committee with pharmaceutical scientists from 
academia and UK industry; this committee provided valuable input throughout the development of 
this review.   
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3. Results and discussion 
Figure 1 shows the results of the search and the screening of literature to identify studies to include 
in this review.  
 
3.1. Study Characteristics 
A total of 61 unique papers were included in the analysis of acceptability, this is 31 additional papers 
compared to a previous review on a similar topic (palatability only) conducted by Davies and Tuleu 
(2008) [8] (17 related to acceptability not limited to palatability and an additional 14 papers on 
palatability were identified). All papers included measured the acceptability of medicines in a 
pediatric population; one paper included data pooled from adults and children as the authors stated 
that the results were similar across these groups [9]. The age of participants ranged from 0-18 years 
across all studies with more than two thirds of studies involving only those aged 12 years or younger 
(full details available within online resource 2). Fifteen studies included participants whose ages 
spanned at least 10 years; this may lead to variability in data capture based on the cognitive function 
of the younger versus older participants within these studies. Only one study reported using age 
based scales to assess acceptability where a simple scale was used for those aged 3-5 and an 
alternative for those aged 6-15 years [10].  
In total 147 products were evaluated although some duplications were found. A table of all studies 
included is available in online resource 2. Brand names were rarely reported within the literature 
which limits the direct comparison between studies as it is already known that therapeutic 
equivalents can have very different organoleptic properties (e.g. [11-22]). 
The number of products evaluated by each individual within a study varied from 1 to 5 with a mean 
value of 2.6 and median value of 2 products tasted by each participant. Only two of the studies 
included a placebo [23, 24]. 
Palatability with an emphasis on taste was the most common acceptability parameter evaluated in 
54 of 61 studies included. Where taste was not assessed, common measures of acceptability 
included: the swallowability of dosage forms (e.g. [25-28]), or the ease of use of a product (e.g. [29, 
30, 19]) with just one study evaluating the volume of liquid swallowed [31]. 
3.2. Methodology used to assess acceptability 
Scale methods were the most popular to be used in assessing the acceptability of medicines in 
children, this includes direct pediatric reports and reports made by parents/carers or healthcare 
professionals on behalf of children. Visual analogue scales (VAS) and hedonic scales were used 
separately and also in combination in 32 of the studies investigated; hedonic scales without VAS 
reported for 16 studies and VAS alone in just 5 studies. Eight studies used a Likert scale alone or 
based on a question (e.g. Five point scale from 0 = disliked the taste a lot to 4=liked the taste a lot 
[32]). Five studies used a forced choice or preference between multiple products to rank their order 
in terms of acceptability. Surveys or questionnaires were used in eight studies.  A range of other 
methods were reported including the observation of facial expressions during administration; the 
ease or ability to swallow the dosage form (e.g. [26, 27]); the prevalence of complaints or refusal to 
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take the medicine was used in one study [19]; and finally, one study evaluated the time taken for a 
nurse to administer the medicine as a measure of acceptability where it was stated that 60 seconds 
was the average administration time.[33]. 
The use of observations to assess swallowing seems to be a recent addition to the battery of tests 
available to assess acceptability, whereas Likert scales have become less popular with time.  
 
3.2.1. Hedonic scales 
Although adult sensory studies typically use a 9-point hedonic scale it has been suggested that fewer 
points are more appropriate for children; with 5-point hedonic scales being suitable for children  
aged 4 and over [34]. The number of faces within hedonic scales used to assess acceptability of 
medicines varied from 2 [10] up to 7 [21]. Gender specific scales were identified (e.g. [35-37]) but, in 
most cases they were gender neutral. The 5-face hedonic scale was most popular and used in 12 
studies; 4 faces were used in 2 studies; 2 and 7 faces were used in one study each. The 2 face scale 
was used specifically in a young population aged 3-5 as a subset of a larger study where 4 faces were 
used in children from 6-15 years [10]. It has been suggested that the inclusion of a middle response 
in scale-based questions can often be selected as an ‘easy way out’ and prevents thought into the 
question being asked [38]. However, in determination of what is acceptable (and not necessarily 
liked) a neutral face seems appropriate. 
In the sensory evaluation of food hedonic scales are used with verbal descriptors for children. Chen 
et al. (1996) showed that 3 faces with verbal descriptors could be used with children from 3-4 years 
and 5 faces from 4-5 years with  a 7 point version being used with children over 5 years.  [34] 
Hedonic scales provide categorical data which can limit the number of statistical tests that can be 
applied, although the more points on the scale the better the tool will be.  Chi squared statistical 
analysis is used to determine whether differences are observed between two products assessed. 
They are proven to be useful for young children although it is critical that the facial expressions are 
meaningful to the participants. These tests rely on a comparison of two products to determine 
whether the score for one product are different to the control. 
Hedonic scales have been demonstrated to be appropriate to use in sensory testing with children 
above the age of 4 [39]. There are also reports of parents interpreting the behaviour of a toddler as 
he/she tasted the food and then reported the child’s acceptance on a hedonic scale [40]. Hedonic 
scales were used with children as young as 3 in several acceptability studies [13, 41, 10, 42, 43, 18]. 
Age-appropriate VAS and hedonic scales are widely used in the assessment of pain in pediatric 
populations and these are often used as the basis for other scales of this type. The Wong-Baker 
FACES Pain Rating Scale has been extensively used in children to rate pain severity and has been 
validated outside the emergency department, mostly for chronic pain [44].  This validated scale 
includes 6 faces and reads from no pain (positive happy face) at the left to most painful (negative 
sad face) at the right. The 9-point hedonic scale that has been the most commonly used scale in 
adult consumer preference and acceptability of foods showed no difference in reports based on 
structural variations; that reads from positive to negative or vice versa [45]. In this review the taste 
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scales reported showed negative (sad face) to positive (happy face) in 22 studies and from positive 
(happy face) to negative (sad face) in 5 studies. 
As with pain, numerous hedonic scales have been developed to measure acceptability of medicines, 
yet it remains unclear whether any of the scales is better for a particular purpose with regard to 
validity, reliability, feasibility, and preference [46]. Table 1 shows a range of hedonic scales used in 
acceptability testing of medicines in children. 
 
3.2.2. Visual Analogue Scales (VAS) 
VAS require selecting a point on a straight line (usually 100mm) representing the dimension of 
agreement with the statements that are written beneath the line (termed anchor phrases). They 
have been extensively researched in the assessment of pain and they show good sensitivity and 
validity for most children at age seven years and older [54, 55]. In the assessment of acceptability of 
a medicine they were used in children as young as 5 years [30]. 
VAS provides continuous data and is better suited to looking at differences between samples as the 
data can be used to set significance levels and analysis via statistical t-tests. However, they are 
limited by the age at which children comprehend their purpose and transpose a feeling or sensation 
to a linear scale. It is also critical that the anchor phrases at the extremes of the scale are 
comprehensible to the participants. The misuse of hedonic and VAS has previously been reported 
(e.g. [56]) where the anchor phrases are not meaningful to the study participants. The anchor 
phrases used in hedonic scales were included in table 1 and those used with VAS are listed in table 2. 
Some studies used a VAS without anchor phrases when in combination with a hedonic scale (e.g. 
[47, 50, 48]). 
3.2.3. Combined VAS and hedonic scales 
Combining VAS with hedonic uses facial expressions in place or as well as anchor phrases to 
generate a tool that is meaningful to participants. In the studies that reported using a combination 
of VAS with hedonic, 5 faces were also most popular with 10 studies using this combination. In one 
study, 10 faces were used [41] and in another 2 faces in combination with the VAS [24]. One study 
stated that a VAS and hedonic were used but no further details were provided [22]. 
A combination of VAS with hedonic images makes statistical analysis complex as this uses both 
categorical and continuous scales therefore subsequent analysis is complicated. A participant is likely 
to select a point on the line that correlates to a face rather than considering the line a continuous 
scale; therefore interpretation of data is flawed. Despite these methodological flaws, it is 
acknowledged that this has become common practice in acceptability testing.  
The results of an industry survey on tools used to assess palatability and swallowability also reported 
that 5-face hedonic scales and VAS were most popular although the data are not clear as to whether 
these were used in combination and this survey only received six responses [62]. 
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3.2.4. Observations of acceptability 
Observations of facial reactions were used in acceptability testing of medicines [63, 53, 60]. Moniot-
Ville et al (1998) used a simple researcher observation of a child, where if the child smiled whilst 
taking the medicine it was rated as good or fairly good; if the child accepted the medicine without 
making faces it was rated as acceptable and if the child made faces or complained about the taste 
this was rated as poor. Verrotti et al (2012) queried parents about their child’s reaction or facial 
expression as a surrogate for palatability, “On the basis of reaction/facial expression of your child, do 
you think that the medication is: pleasant; not sure or unpleasant?”  
Three studies which investigated the use of minitablets in children used observations to assess the 
acceptability where swallowing of the dosage form, even with chewing, was reported as an 
acceptable formulation [26, 28, 27]. 
Other studies used parent reported outcomes of acceptability where observations of behaviour, and 
facial expressions were likely to form the basis for this, although this was not explicitly stated [64, 
14, 57, 17, 65, 19, 66, 61]. 
A more detailed protocol of observations was reported by Saez-Llorens (2009) based on a study that 
assessed the acceptability of famciclovir pediatric formulation [60]. Parents were asked to report the 
acceptability of taste and aftertaste using the statements listed below which were aligned to 
hedonic scales: 
1. Very badly accepted/unacceptable: child showed great displeasure compromising use of 
formulation 
2. Badly but accepted: child showed displeasure with dosing but could be coaxed to take 
complete dose 
3. Neither good nor bad: child showed no apparent displeasure and with little effort was 
coaxed to take complete dose 
4. Well accepted: child appeared to enjoy the formulation with little coaxing ingested most of 
dose 
5. Very well accepted: child appeared eager and ingested most of dose without special coaxing 
 
3.2.5. Other tools used to assess acceptability 
Likert scales (verbal or written categorical response scales) have also been used in the evaluation of 
acceptability of pediatric medicines. In many cases, Likert scales were combined with facial 
expressions or used within a questionnaire with responses including: 1 = very tasty to 5 = very bitter 
[67]; 0 = disliked the taste a lot to 4 = liked the taste a lot [32]. 
Spontaneous verbal reactions were also captured in some studies (e.g. [21, 18, 12]).These are of 
value as palatability or acceptability is a subjective measure and the reasons for non-acceptance are 
critical in adapting the medicine for that individual. The prevalence of complaints or refusals has also 
been recorded (e.g. [19]) and this data is of value as it records the longer term acceptability, or 
compliance with the medication which can be essential for therapeutic success. The child’s 
willingness to take the medicine again has also been recorded in some studies (e.g. [23, 48]). 
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One study recorded the time taken by a nurse to administer the medicine as a surrogate for 
acceptability [33]. 
3.3. Criteria to define acceptability 
Despite identification of 61 unique literature reports on the acceptability of medicines for pediatric 
populations only 10 stated criteria (listed in Table 3) used to define an acceptable product; this 
needs to be addressed in reports going forwards. 
A more detailed definition of acceptability was reported that used descriptors aligned to a hedonic 
scale to classify medicines as unacceptable to very well accepted [60]; these descriptors of 
acceptability ensured that participants, in this case parents, were aware of the parameter under 
evaluation. A simple report based on caregivers reports of their child and their perception of the 
taste being better, the same or worse than other medicines has also been reported [68]. Proxy 
reports by parents or carers on the acceptability of a medicine may be a useful method to 
triangulate patient responses from VAS or hedonic scales to assess the validity of such scales. 
In veterinary medicine, non-acceptance is characterised as delayed uptake; partial uptake; 
regurgitation, spitting out the product or direct refusal [69]. Other reports of rejection behaviours in 
sensory testing include a child closing their mouth firmly, pushing the food/drink away, crying or 
spitting out the tastant [70, 71]. 
 
3.4. Statistical methodology in acceptability assessment 
The evaluation of acceptability needs to be underpinned by robust statistical methodology. 
However, there have been very limited reports of the application of statistics to acceptability testing    
or of an up-front definition of the hypothesis or criteria for acceptance as reported in Table 3. 
Existing criteria for acceptance are somewhat limited. A value of 80% of the sample population in 
agreement that the product is acceptable is generally considered to be the current standard 
requirement. This 80% threshold value was used in proposed regulatory guidelines on the 
demonstration of palatability of veterinary medicinal products; which may be similar to 
considerations given to the palatability of medicines for human use  [5]. The choice of sample size is 
complex in this type of analysis, as previously highlighted from the literature on consumer rejection 
threshold values in sensory assessment [72]. 
The literature review conducted demonstrated that the size of the study population varied from 10 – 
769 participants, with an average number of 112.6 and a median number of 46 participants 
evaluating each product. EMA veterinary guidance on palatability proposed a sample size of 50 
animals if the product is only observed once or 25 if the product is administered on at least two 
occasions; the statistical justification for this is not recorded but the sample sizes are similar to those 
used in sensory analysis for acceptance [5]. Use of the total number that accept a product is more 
robust than providing a mean VAS or hedonic score as a mean value may not accurately reflect the 
extremes within the population. The sample size used in sensory testing is also widely debated and is 
dependent upon the methodology used and the ultimate endpoint. An adequate sample size, to be 
able to document clear sensory differences in foods, when performing discrimination tests is 25-40 
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participants [73]. Nevertheless, some discrimination tests can be performed with as few as six 
participants if differences between samples are large and there are trained panellists [74]. 
In sensory testing conducted in adults, assessment of differences in two products using either 
hedonic or visual analogue scales will depend upon the size of difference you consider significant 
and also the competence of the assessors [75]. Statistical analysis is typically via a t-test for two 
items and an ANOVA for more than two. A significant ANOVA result may be compared using an 
appropriate post hoc test depending upon the distribution of data. In cases where different groups 
of participants are trying different products a simple chi-squared test can be performed. 
There have been studies that have reported the statistical parameters used when comparing the 
tastes of more than one sample. For example, when assessing acceptability of zinc dispersible tablets 
[65], Nasrin et al (2005) proposed a sample size of 140 children per group to identify a +/- 7.5% 
difference in acceptability when acceptability is set at 70% with a level of confidence of 95%; this 
study required parents to report whether the medicine was better, same or worse than other 
medicines with responses of the same or better being recorded as acceptable.  Thompson et al 
(2015), proposed using a non-inferiority test to a reference product where, to achieve a significance 
level of 0.05, a sample size of 50 subjects was required based on a VAS scale although basis for this 
methodology is missing from the original reference [6]. The most important aspect is the clinical 
significance of a change which needs to be considered as it is feasible that both the reference and 
sample product are either acceptable or unacceptable depending on the values of the scale. This has 
previously been observed using pain scales when a child’s pain level has diminished from 8 to 7 
following intervention, but does this necessarily represent a success in treatment?  
 
4. Conclusions 
There are many measurements reported that assess the acceptability of medicines designed for 
children, however a standardised methodology has not yet been identified and may not be possible 
due to the wide range in ages and products that require evaluation. It is important that a scale to 
assess acceptability is suitable for that intended purpose.  
A robust method that allows assessment of acceptability of a pediatric medicine, within the target 
population is urgently required. Pain scales are an established tool used with children; Hester et al. 
(1998) collated a number of desirable features that pain scales for children should have, including: 
- Developmentally and culturally appropriate to participants (i.e. within the child’s cognitive and 
language skills) 
- Easily and quickly understood by participants who have minimal formal education 
- Well-liked by participants and clinicians 
- Places low burden on clinician and participant 
- Inexpensive and easy to obtain, reproduce and distribute to clinicians, participants and their 
families 
 
Existing VAS and hedonic scales are likely to be preferred by those administering and undertaking 
the evaluation as they meet the criteria outlined above. The use of space, graphics, underlining, bold 
type, colour, shading and other qualities of design can affect how participants react and engage with 
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a questionnaire [76]. It is important that the images used are meaningful to the participants within 
the study. It has been reported that children prefer hedonic scales to VAS when given a choice [77]. 
A definition on what the meaning of acceptable is in a clinical setting in addition to that provided is 
required to drive the development of the most appropriate scale such that the sample size, 
statistical analysis and endpoints allow classification of the medicines under test as either acceptable 
or not. This may be linked to the use of a standardised control, for example, in taste evaluation 
whether the medicine under test is better or worse than the control is used. A standardised 
methodology would allow better comparisons in acceptability across studies and enable 
comparisons of products to define which are better accepted within a given population provided a 
better link to clinical relevance. Such methodology would be beneficial both to those working in the 
development of pediatric medicines and for regulators involved in the approval of pediatric 
medicines. The tool to assess acceptability may influence the overall results therefore the definition 
needs to be related to the tool under use. Using the existing definition of acceptability, “an overall 
ability of the patient and caregiver (defined as ‘user’) to use a medicinal product as intended (or 
authorised)” [3]; observations are a useful part of the overall toolkit that should be used to assess 
acceptability. 
It remains unclear as to which scale is the best with regard to validity, reliability, feasibility and 
preference. Current practice demonstrates that hedonic and visual analogue scales are most used 
and these seem appropriate at this stage. Further work required in this area includes an evaluation 
of an appropriate standardised scale within the relevant population to ensure that the descriptors 
are meaningful and that the resulting data is reliable rather than developing new scales (as there are 
already so many). 
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Figure 1. Flow diagram of study identification and selection 
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Search word Remit Results 
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 2 Medicine Within results above 94688 
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Within results above 28432 
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swallowability 
Within results above 7284 
     
PubMed 5 Acceptability OR preference Title/abstract 16398 
 6 Medicine Title/abstract 4474574 
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Title/abstract 118121 
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 16 Medicine keyword 47280 
 17 Child OR infant OR pediatric OR 
paediatric 
keyword 2433874 
 18 palatability OR taste OR smell OR 
size OR shape OR appearance OR 
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Online Resource 1. Summary of studies included in the review detailing methodology reported for acceptability testing of medicines in children 
 Reference Dosage form (drug) Dosage form (formulation) 
Test population 
(n=) 
Test population 
(age range) 
Tool used (VAS alone; VAS 
+ hedonic; hedonic alone; 
open question; forced 
choice/preference) 
Number of 
faces in 
hedonic 
scale 
[13]  Trimethoprim-
sulfamethoxazole,  Biocraft 
= generic, Cephalexin 
monohydrate (Biocraft) = 
generic, Cephalexin 
monohydrate Dista (Keflex 
®) = brand, erythromycin/ 
sulfosoxazole Alra= generic, 
erythromycin/sulfosoxazole 
Ross (Pediazole®)= brand, 
sulfamethoxazole, Roche 
(Bactrim®)= brand  
Liquid 16 3-14 years Hedonic alone 5 
[16] Prednisolone (generic) 
Prelone vs Orapred 
Liquid 18 6-10 years Hedonic alone 5 
[17] Colecalciferol vide3 vs 
Oleovit D3 
Liquid 70 <81 days Hedonic alone (parent 
reported) 
4 
[58] Amlodipine besylate 
(Norvasc) vs lercanidipine 
(Zanidip) 
Liquid (crushed tablets)  20 4-11 years Hedonic alone 5 
[10] Sodium valproate Prolonged release 
granules 
(Micropakine®) vs 
liquid 
236 3-15 years Hedonic alone 2 (for under 
5s) 
4 (for over 
5s) 
[42] Mercaptopurine oral 
suspension (Xaluprine(R)) 
Liquid 22 3-16 years Hedonic scale plus 
open/closed questions 
5 
[36] Clarithromycin vs 
cefpodoxime proxetil vs 
cefprozil  vs azithromycin vs 
cefixime vs loracarbef 
Liquid 769 4-12 years Gender specific hedonic  
After both medications 
were taken the child was 
asked which medication 
had the preferable taste 
and colour. 
5 
[37] Amoxicillin/clavulanate 
potassium vs cefprozil  vs 
azithromycin vs cefdinir 
Liquid 148 4-8 years Gender specific  hedonic 
scale  
5 
[60] Famciclovir  Liquid (sprinkle capsule 
mixed with 5 ml 
orasweet immediately 
prior to dosing) 
51 1-12 years Hedonic scale 5 
[43] Cefuroxime axetil vs 
clarithromycin vs 
cefpodoxime proxetil vs 
amoxicillin 
Liquid 153 3-8 years Hedonic scale 5 
[20] Ondansetron  Liquid 59  Not stated Hedonic scale 5 
[78] Ranitidine vs lansoprazole Liquid 110 5- 11 years Hedonic scale 5 
[79] Ranitidine vs lansoprazole Liquid vs orally 
disintegrating tablet 
104 6-11 years Hedonic scale 5 
[53] Valproate Multipartculate 
sprinkle 
108 Mean age 6.7 years Hedonic 5 
[21] Amylmetacresol and 2,4-
dichlorobenzyl (AMC/DCBA)  
Lozenge 102 6-12 years Hedonic scale. The 
spontaneous reaction of 
the child on tasting each 
lozenge was observed and 
recorded.  
7 
[18] Bacampicillin (5 brands) Liquid 19-23 3-12 years Hedonic scale plus 
spontaneous verbal 
judgement 
5 
[59] Activated charcoal Liquid 44 14-19 years VAS  
[14] Paracetamol Parapaed vs 
Paracare double strength 
Liquid 106 6-18 years VAS alone 
Parent and nurse 
estimations on a VAS scale 
  
[30] Desmopressin lyophilisate  Dispersible tablet 
(MELT) vs conventional 
oral tablet 
221 5-15 years VAS   
[57] Prednisolone Liquid vs crushed 
tablets 
35 0.25 - 8 years VAS alone (parent 
reported) 
  
[61] Placebo Tablet; powder; liquid 148 1-4 years VAS and observation of 
intake (parent reported) 
  
[52] Strawberry-, orange- and 
cherry-flavoured oral 
artemether-lumefantrine 
suspension 
Liquid 48 7-10 years VAS + hedonic 5 
[47] Amoxicillin-clavulanic acid 
(Augmentin), cefprozil 
(Cefzil), azithromycin 
(Zithromax), cefixime 
(Suprax) 
Liquid 30 5-8 years VAS + Hedonic 5 
[50] Activated charcoal Liquid 30 5-9 years VAS + Hedonic 5 
[48] Oral rehydration Enfalyte, 
Pedialyte, Pediatric 
electrolyte 
Liquid 66 5-10 years VAS + Hedonic 
Volume Consumed 
Would you take this 
again? 
Preference 
5 
[41] Activated charcoal (Liqui-
Char) + flavourings 
Liquid 53 3-17 years VAS + Hedonic 10 
[49] Prednisolone vs 
dexamethasone 
Liquid 39 5-12 years VAS + Hedonic 5 
[80] Cloxacillin vs fusidic acid vs 
cephalexin vs erythromycin 
Liquid 20 6-12 years VAS + Hedonic 5 
[81] Clarithromycin vs 
erythromycin vs amoxicillin 
and clavulanic acid vs 
azithromycin   
Liquid 50 Mean age 6.3 years VAS + Hedonic 5 
[35] Valsartan vs losartan vs 
ibesartan vs telmisartan vs 
candesartan cilexitil 
Crushed tablets  21 4-11 years VAS + Hedonic (gender 
specific) 
5 
[24] Ibuprofen   Liquid 151 4-7 years VAS + Hedonic (2 faces sad 
and happy) 
2 
[51] Codeine (Thornton and Ross 
Limited, Linthwaite, 
Huddersfield, UK) vs 
paracetamol (SSL 
International PLC) vs 
ibuprofen (Pinewood) 
Liquid 21-66 5-16 years VAS + hedonic 5 
[82] Amoxicillin/clavulanate vs 
cefprozil vs azithromycin vs 
cefixime 
Liquid 90 5-9 years VAS + Hedonic 5 
[22] Ampicillin-cloxacillin 
(Emzorclox) vs cefuroxime 
axetil (Zinnat) vs amoxicillin-
clavulanate (Fleming, 
Medreich) vs cefixime 
(Zemicef) 
Liquid 24 6-11 years VAS + Hedonic Not stated 
[83] Clonidine + ibuprofen 
mixture (Nureflex®)  
Liquid vs intranasal 
spray 
20 1.2-6.5 years Three-point Likert scale 
was applied for evaluation 
of taste: 1 = good, 2 = 
indifferent, 3 = bitter, 
unpleasant 
 
[64] Amoxicillin/clavulanate vs 
Cefixime 
Liquid 155 0.5-12 years A Likert scale ranging from 
1 (disliked) to 3 (liked a 
lot) was used for the 
following question: 
Child liked taste of 
medicine 
  
[15] Pivampicillin (Pondocillin) Liquid 45 1-7 years Likert scale question: state 
whether the medicine 
tasted "very good" = 2; 
good = 1 or bad = 0 
  
[84] Cholestyramine Tablet vs powder 38 10-18 years 6-point Likert scale   
[32] Ibuprofen vs paracetamol Liquid 42 0.4-11.6 years Five point Likert scale 
from 0 = disliked the taste 
a lot to 4=liked the taste a 
lot 
 
[63] Roxithromycin  Liquid (tablet for 
suspension) 
210 2-8 years Likert scale and 
observation of child facial 
responses 
  
[67] Carbamazepine vs valproate Tablets (crushed) Not stated 5-12 years Likert scale   
[66] Pancrelipase Microtablets 16 0.5-2.5 years Likert scale  
Parental assessment of 
palatability using a 4 point  
  
[28] Placebo Minitablets 60 0.5-6 years Observations that the 
child swallowed the 
minitablets 
  
[19] Dexamethasone vs 
prednisolone 
Liquid 80 1-11 years Ease of taking and 
prevalence of 
complaints/refusal 
  
[26] Placebo Minitablets vs liquid 306 0.6-5 years Observations of the ability 
to swallow the dosage 
form (not refuse or reject 
it) 
  
[27] Placebo Minitablets in jelly 30 2-3 years Observations of the ability 
to swallow the dosage 
form (not refuse or reject 
it) 
  
[85] Vivotif BERNA oral typhoid 
vaccine 
Enteric coated capsule 434 4-15 years Observations of the ability 
to swallow 3 capsules 
without breaking them 
  
[11] Ranitidine Liquid (Zantac®) vs 
effervescent tablet 
(Zantac ® Efferdose) 
102 4-8 years Forced choice preference 
question 
 
[86] Antiretroviral therapy Liquid and tablets 267 0.25-17 years Questionnaires to 
caregivers about issues 
with formulations and a 
preference 
  
[65] Zinc sulfate Liquid (dispersible 
tablet) 
303 0.25-5 years Questionnaire with 
response options better, 
same, or worse than other 
medicines 
  
[87] Creon ® Minimicrospheres 
within a capsule vs 
conventional 
microspheres 
51 3-17 years Preference based on ease 
of swallowing 
presence/absence of an 
aftertaste and feeling of 
fullness after the capsule 
  
[88] Oral montelukast and 
inhaled cromolyn 
Chewable tablet of 
montelukast or 
comolyn via metered 
dose inhaler 
236 6-11 years Child satisfaction 
questionnaire and 
preference 
  
[29] Inhaled corticosteroids with 
either zafirlukast tablets or 
inhaled beclomethason 
Inhaler plus tablets vs 
inhaler plus inhaler 
132 12-17 years Questionnaire on 
preference and ease of 
use 
  
dipropionate 
[25] Oral medicine (not 
specified) 
Number of tablets that 
are acceptable 
202 5-11 years Survey - questionnaire  
[12] Phenoxymethylpenicillin Liquid 316 3-10 years Open question (scored 
verbal assessment 
following a non-leading 
open question) 
 
[89] Valproate Sprinkle vs liquid 12 5-16 years Questionnaire with 
preference of sprinkle vs 
syrup 
  
[90] Ondansetron vs placebo Orally disintegrating 
tablet 
31 5-11 years Each child was asked to 
evaluate the tablet 
according to taste, 
sensation, and willingness 
to take the medication in 
the future 
  
[31] Pediapred (1 mg/ml; 
Medeva, Surrey, UK) vs 
Prelone (3 mg/ml; Muro 
Pharmaceuticals, 
Tewksbury, MA) 
Liquid 51 < 10 years Survey - questionnaire  
[91] Antimicrobial suspensions 
used to treat otitis media 
Liquid 16 Not stated Score out of 10 for 
appearance; smell; 
texture; taste and 
aftertaste 
  
[9] Oral rehydration solution 
(flavours) 
Liquid 30 Adults and children Grade as good, not good 
or bad 
  
[33] Erythromycin ethylsuccinate 
vs phenoxymethyl-penicillin 
potassium 
Liquid 20 0.2-8 years The time a nurse required 
to give the drug to a child 
was recorded and a score 
of the acceptance was 
given by the nurse. 
  
 
Table 1. Overview of hedonic scales used in acceptability studies in children  
Comments Reference 
Two gender specific 5-face hedonic scales used in children aged 4- 8 years to 
assess palatability of antibiotic suspensions.  
Male faces were shown to male subjects and female faces to female subjects. 
The expression change is demonstrated by changes in the eyes, eyebrows and 
mouth.  
The age of the child images reflects the age of the participants 
The scale direction was positive at the left to negative at the right 
[37, 36] 
A 5-face hedonic scale used to assess palatability of a range of medicines in 
children aged 3-16 years. 
The faces are gender neutral with no hair and the only expression change is the 
mouth. 
The scale direction was negative at the left to positive at the right 
[47-51] 
[42, 52] 
A 5-face hedonic scale used to assess the palatability of modified release granule 
formulation of valproate 
The faces are gender neutral with no hair. The expression change is demonstrated 
by changes in the eyes, eyebrows and mouth. The negative face shows tears and 
the most positive face is winking.  
The scale direction was negative at the left to positive at the right 
[53] 
A 5-face hedonic scale proposed as the best practice scale for assessing 
palatability of paediatric medicines by the Global Alliance for Pediatric 
Therapeutics, a public–private consortium under the guidance of the Institute for 
Pediatric Innovation 
The faces are gender neutral with no hair. The expression change is demonstrated 
by changes in the eyes, eyebrows and mouth.  
The scale direction was negative at the left to positive at the right 
[6] 
Two hedonic scales used to assess the acceptability of a microgranule formulation 
of sodium valproate. 
Children aged 3-5 used a 2 face scale and those aged 5-14 a four face scale 
The faces are gender neutral with short hair. The expression change is 
demonstrated by changes in the eyes and mouth. The negative face shows tears.  
The scale direction was negative at the left to positive at the right 
[10] 
 
Table 2. List of phrases used in VAS to assess acceptability of medicines in children  
Phrases  Reference 
I did not like it I liked it very much [52] 
Did not like at all        Liked very much [14] 
I find it very easy to use this 
medicine 
I find it very difficult to use this 
medicine 
[30] 
Nice taste Foul taste [57] 
Really good              Really bad [35, 58] 
Bad Good [42, 59] 
Very poor taste Very good taste [60] 
Very much unpleasant, 
bothersome* 
Not at all unpleasant, 
bothersome* 
[61] 
*This is a direct translation from a Dutch study  
 
Table 3. Literature reports of criteria to define acceptability of medicines 
Limit of acceptance/palatability Products deemed to be acceptable  Study 
reference 
Hedonic Scales   
In a 2 face hedonic the positive face was 
considered acceptable = score >1/2  
In the 4 face hedonic the two positive 
faces were considered acceptable = score 
>2/4 
33-43% of children found the sodium 
valproate syrup acceptable  
77-88% of children found the sodium 
valproate sustained release granule 
acceptable 
[10] 
In a 5 point hedonic scale; neutral to 
positive was recorded of acceptable = 
score >2/5 
17/22 (77%) participants reported that 
the taste was neutral to positive which 
was considered to be acceptable 
[42] 
Excellent palatability = mean score of 
4.21/5 
The amoxicillin reference product was 
stated to have excellent palatability 
[43] 
Acceptable taste = mean score of 3.4/5 
Unacceptable taste = mean score of 2.1/5 
Two products were included that were 
stated to be acceptable and unacceptable 
in terms of taste 
Acceptable taste was brand W penicillin 
Unacceptable taste was brand U penicillin 
[18] 
Primary endpoint was % of participants 
with a score of >4/7 
85.3 % of subjects found the strawberry 
flavour lozenge to be acceptable and 49.0 
% for the orange flavour lozenge 
[21] 
Visual Analogue Scale   
50mm point on a 100mm VAS  stated to be 
ambivalent taste, scores above 50 mm are 
palatable 
Paracare double strength paracetamol 
stated to be palatable and acceptable 
compared to Parapaed 
[14] 
Observations/Carer reports   
A child accepting the drug without making 
faces or smiling whilst observed taking the 
medicine 
70.5% of children accepted roxithromycin 
tablet for suspension 
[63] 
Observations were used to assess 
swallowing of the dosage form. Swallowing 
the dose, even with chewing, was 
measured as an acceptable formulation 
Minitablets 2-3 mm in diameter are 
acceptable to children ≥ 6 months 
When suspended in jelly up to 10 
minitablets are acceptable as a single 
dose 
[26, 28, 
27] 
Carers needed to state that the product 
was equally or more acceptable to their 
child than other medicines (70% of 
population agreeing was used as basis for 
statistical powering) 
93.1 % of the treated children thought 
that zinc tablets were equally or even 
more acceptable than other medicines. 
83.5% of caretakers stated that they 
would use these tablets again 
[65] 
   
 
